Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Fw: Press Release - Advancing HCV Drug Development: A Collaborative Approach

Posted Dec 14 2010 12:00am
------Original Message------
From: Veronica Miller, on behalf of the Forum for Collaborative HIV Research
Sender: Veronica Miller, on behalf of the Forum for Collaborative HIV Research
To: Nelson Vergel powertx
ReplyTo: Veronica Miller, on behalf of the Forum for Collaborative HIV Research
Subject: Press Release - Advancing HCV Drug Development: A Collaborative Approach
Sent: Dec 14, 2010 4:22 PM

Email not displaying correctly? View it in your browser. Contact: Veronica Miller 202-974-6290 veronicam@berkeley.edu   Nancy Glick 202-261-2884 nancy.glick@mslworldwide.com   Hepatitis Experts Create Roadmap for Accelerating the Development of Targeted Therapies for Hepatitis C Virus   WASHINGTON, DC (December 14, 2010) – To improve the care for individuals infected with the hepatitis C virus, a major health problem and a leading cause of chronic liver disease around the world, nearly 200 international hepatitis experts have taken an important step in escalating the introduction of a new class of targeted therapies for HCV -- direct-acting antivirals (DAAs).   Meeting December 6 at a major scientific meeting -- Advancing HCV Drug Development: A Collaborative Approach -- convened by the Forum for Collaborative HIV Research, researchers, hepatitis advocates, members of industry and representatives from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) created the roadmap for accelerating the development of DAAs, agreeing that this new class of drugs targeting specific hepatitis C virus proteins has the same potential to improve treatment outcomes for people with HCV as antiretroviral drugs changed the standard of care in HIV. Currently, two DAA compounds have advanced into phase 3 development in the United State and EU, and many more are in phase 2 trials and likely to advance to the phase 3 research phase in the near future.   "If there was ever a time when we can change the course of HCV, it is now," said Veronica Miller, Ph.D., Director of the Forum. "We are now where we were with HIV more than a decade ago and can apply many of the lessons learned from HIV drug development to significantly accelerate the progress in bringing new and better HCV therapies to market."   DAAs directly attack the ability of the hepatitis C virus to replicate and can increase the cure rate in certain HCV patients to between 60 and 70 percent– a major advance over the 40 percent success rate associated wi
Sent via Blackberry

Post a comment
Write a comment: